4.8 Review

Engineering precision nanoparticles for drug delivery

期刊

NATURE REVIEWS DRUG DISCOVERY
卷 20, 期 2, 页码 101-124

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41573-020-0090-8

关键词

-

资金

  1. Burroughs Wellcome Fund Career Award at the Scientific Interface (CASI), a US National Institutes of Health (NIH) Director's New Innovator Award [DP2 TR002776]
  2. American Cancer Society [129784-IRG-16-188-38-IRG]
  3. NIH [R01-EB022025-4, R01-EB-00246-21, NCI R01 CA241661, NCI R37 CA244911, NIDDK R01 DK123049]
  4. Abramson Cancer Center (ACC)-School of Engineering and Applied Sciences (SEAS) Discovery Grant [P30 CA016520]
  5. 2018 American Association for Cancer Research (AACR)-Bayer Innovation and Discovery Grant [18-80-44-MITC]
  6. UT-Portugal Collaborative Research Program (CoLAB)
  7. National Science Foundation [1033746]
  8. Pratt Foundation
  9. Cockrell Family Regents Chair
  10. NSF Graduate Research Fellowships
  11. National Science Foundation (NSF) Graduate Research Fellowship [DGE 1845298]
  12. NIH Training in HIV Pathogenesis T32 Program [T32 AI007632]

向作者/读者索取更多资源

The development of nanoparticles has shown promising clinical applications, overcoming the limitations of therapeutic interventions and biological barriers. Precision therapies have enhanced treatment efficacy through personalized interventions. Advancements in nanoparticle design aim to optimize drug delivery, improving efficacy in general applications and enabling tailored designs for precision applications.
In recent years, the development of nanoparticles has expanded into a broad range of clinical applications. Nanoparticles have been developed to overcome the limitations of free therapeutics and navigate biological barriers - systemic, microenvironmental and cellular - that are heterogeneous across patient populations and diseases. Overcoming this patient heterogeneity has also been accomplished through precision therapeutics, in which personalized interventions have enhanced therapeutic efficacy. However, nanoparticle development continues to focus on optimizing delivery platforms with a one-size-fits-all solution. As lipid-based, polymeric and inorganic nanoparticles are engineered in increasingly specified ways, they can begin to be optimized for drug delivery in a more personalized manner, entering the era of precision medicine. In this Review, we discuss advanced nanoparticle designs utilized in both non-personalized and precision applications that could be applied to improve precision therapies. We focus on advances in nanoparticle design that overcome heterogeneous barriers to delivery, arguing that intelligent nanoparticle design can improve efficacy in general delivery applications while enabling tailored designs for precision applications, thereby ultimately improving patient outcome overall. Advances in nanoparticle design could make substantial contributions to personalized and non-personalized medicine. In this Review, Langer, Mitchell, Peppas and colleagues discuss advances in nanoparticle design that overcome heterogeneous barriers to delivery, as well as the challenges in translating these design improvements into personalized medicine approaches.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据